Showing 61-80 of 503 for: Cochrane Systematic Reviews > Neurologic 
- Benzodiazepines for alcohol withdrawal
Cochrane Systematic Reviews, 14-Feb-2010
Alcohol abuse and dependence represents a serious health problem worldwide with social, interpersonal and legal interpolations. Benzodiazepines have been widely used for the treatment of alcohol withdrawal symptoms. Moreover it is unknown whether differen
- Benzodiazepines for neuroleptic-induced tardive dyskinesia
Cochrane Systematic Reviews, 18-Jan-2012
Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by the use of neuroleptic drugs. A wide range of strategies have been used to help manage tardive dyskinesia, and for those who are unable to have
- Beta-blocker therapy for tremor in Parkinson's disease
Cochrane Systematic Reviews, 11-Nov-2008
The tremor of Parkinson's disease can cause considerable disability for the individual concerned. Traditional antiparkinsonian therapies such as levodopa have only a minor effect on tremor. Beta-blockers are used to attenuate other forms of tremor such as
- Betahistine for Ménière's disease or syndrome
Cochrane Systematic Reviews, 7-Feb-2011
This is an update of a Cochrane Review first published in The Cochrane Library in Issue 1, 2001 and previously updated in 2008.
- Biopsy versus resection for high grade glioma
Cochrane Systematic Reviews, 11-Feb-2015
Patients with a presumed high grade glioma (HGG) identified by clinical evaluation and radiological investigation have two initial surgical options; biopsy or resection. In certain situations, such as severe raised intra-cranial pressure, surgical resecti
- Biopsychosocial rehabilitation for upper limb repetitive strain injuries in working age adults
Cochrane Systematic Reviews, 4-Nov-2008
Upper limb repetitive strain injury is a common problem in western countries, causing human suffering and huge economical losses. Patients with prolonged pain associated with repetitive tasks in the work place can face both psychological and physical diff
- Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia
Cochrane Systematic Reviews, 9-Aug-2009
This is an update of a previous review (McGuinness 2006).
- Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE)
Cochrane Systematic Reviews, 10-Nov-2009
Cerebral palsy (CP) is "a group of permanent disorders of the development of movement and posture causing activity limitation(s) that are attributed to non-progressive disturbance that occurred in the developing fetal or infant brain" (Rosenbaum 2007, p.9
- Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy
Cochrane Systematic Reviews, 12-Nov-2008
Children with cerebral palsy often have spasticity of the legs, a condition in which the legs are stiff because of involuntary muscle overactivity caused by the brain or spinal cord disorder. Spasticity causes poor coordination, spasms, abnormal posture a
- Bradykinin beta-2 receptor antagonists for acute traumatic brain injury
Cochrane Systematic Reviews, 20-May-2010
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Cerebral oedema, the accumulation of fluid within the brain, is believed to be an important contributor to the secondary brain damage that occurs following injury. The rele
- Bright light therapy for sleep problems in adults aged 60+
Cochrane Systematic Reviews, 11-Nov-2008
The prevalence of sleep problems in adulthood increases with age. While not all sleep changes are pathological in later life, severe disturbances may lead to depression, cognitive impairments, deterioration of quality of life, significant stresses for car
- Bromocriptine for levodopa-induced motor complications in Parkinson's disease
Cochrane Systematic Reviews, 13-Nov-2008
Motor Complications are an important issue in the management of patients with Parkinson's disease and dopamine agonists have been introduced to ameliorate this problem.
- Bromocriptine versus levodopa in early Parkinson's disease
Cochrane Systematic Reviews, 12-Nov-2008
Drugs that mimic dopamine as bromocriptine were introduced as monotherapy or in combination with LD in the hope that this approach would prevent or delay the onset of motor complications in patients with Parkinson's disease (PD). However, hitherto, the ro
- Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease
Cochrane Systematic Reviews, 12-Nov-2008
Drugs that mimic dopamine, such as bromocriptine (BR), were introduced as monotherapy or in combination with levodopa (LD) in the hope that this approach would prevent or delay the onset of motor complications in patients with Parkinson's disease (PD). Ho
- Cabergoline for levodopa-induced complications in Parkinson's disease
Cochrane Systematic Reviews, 16-Dec-2015
Long term levodopa therapy in Parkinson's disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can
- Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease
Cochrane Systematic Reviews, 16-Dec-2015
Long term levodopa therapy in Parkinson's disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can
- Calcium antagonists as an add-on therapy for drug-resistant epilepsy
Cochrane Systematic Reviews, 27-Feb-2013
This is an updated version of the original Cochrane review published in The Cochrane Library 2001, Issue 4.
- Calcium channel blockers for acute traumatic brain injury
Cochrane Systematic Reviews, 12-Aug-2008
Acute traumatic brain injury is a major cause of death and disability. Calcium channel blockers (calcium antagonists) have been used in an attempt to prevent cerebral vasospasm after injury, maintain blood flow to the brain, and so prevent further damage.
- Calcium channel blockers for neuroleptic-induced tardive dyskinesia
Cochrane Systematic Reviews, 1-May-2013
Schizophrenia and related disorders affect a sizable proportion of any population. Neuroleptic (antipsychotic) medications are the primary treatment for these disorders. Neuroleptic medications are associated with a variety of side effects including tardi
- Cannabinoids for epilepsy
Cochrane Systematic Reviews, 4-Mar-2014
Marijuana appears to have anti-epileptic effects in animals. It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy.
